---
title: 'T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell
  Subsets in the Tumor Microenvironment'
date: '2023-07-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37511431/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230729181031&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Therapeutic options for metastatic colorectal cancer (mCRC) are very
  limited, and the prognosis using combination therapy with a chemotherapeutic drug
  and a targeted agent, e.g., epidermal growth factor receptor or tyrosine kinase,
  remains poor. Therefore, mCRC is associated with a poor median overall survival
  (mOS) of only 25-30 months. Current immunotherapies with checkpoint inhibitor blockade
  (ICB) have led to a substantial change in the treatment of several cancers, such
  as melanoma ...
disable_comments: true
---
Therapeutic options for metastatic colorectal cancer (mCRC) are very limited, and the prognosis using combination therapy with a chemotherapeutic drug and a targeted agent, e.g., epidermal growth factor receptor or tyrosine kinase, remains poor. Therefore, mCRC is associated with a poor median overall survival (mOS) of only 25-30 months. Current immunotherapies with checkpoint inhibitor blockade (ICB) have led to a substantial change in the treatment of several cancers, such as melanoma ...